ArticleInternational journal of nanomedicine2025
A Cell Membrane-Coated Gold Nanoparticle-Based Drug Delivery System for Enhanced Antitumor Therapy in Breast Cancer.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Doxorubicin (DOX) is a first-line chemotherapeutic agent widely recognized for its efficacy in inhibiting tumor growth. However, its clinical utility is limited by systemic toxicity, adverse side effects, and the emergence of multidrug resistance. To address these challenges, we developed a cell membrane-coated nanodrug delivery system in which DOX is loaded onto gold nanoparticles (AuNPs) via electrostatic adsorption, with the cell membrane acted as a biomimetic targeting component to improve therapeutic outcomes and reduce off-target toxicity. Methods: The successful construction of M@DOX@AuNPs was confirmed by UV-Vis absorption spectroscopy and transmission electron microscope. Antitumor effects were evaluated through both in vitro and in vivo experiments. Biological safety was evaluated via histopathological staining and blood biochemical analysis. Results: M@DOX@AuNPs demonstrated favorable physical stability and exhibited time-dependent drug release profiles. Cellular uptake studies revealed that M@DOX@AuNPs were internalized more efficiently in 4T1 and MDA-MB-231 cells compared to free DOX or DOX@AuNPs. Moreover, M@DOX@AuNPs significantly inhibited tumor cell viability and induced apoptosis in vitro, whereas free AuNPs or cell membranes alone showed no detrimental effects on tumor cell viability. In a mouse tumor model, M@DOX@AuNPs exhibited pronounced anti-tumor efficacy without inducing structure damage to major organs or causing significant alterations in blood cell counts and serum biochemical markers. Conclusion: These findings indicate that M@DOX@AuNPs represent a promising targeted chemotherapeutic agent for improved tumor therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.